🟢 MRNA is trading 4.2% up today on regulatory progress for its flu vaccine

MRNA is trading 4.2% up now at $72.59, extending a sharp multi-day rally driven by regulatory progress on its mRNA flu vaccine, mFlusiva.

• The move follows recent FDA advisory panel support and constructive briefing documents for the vaccine candidate.
• Market sentiment is further bolstered by optimism regarding Moderna’s broader clinical pipeline and recent leadership changes.
• The stock continues to show strength as broader market indices trade moderately higher.